Navigation Links
Life Technologies Launches GeneArt® Precision TALs
Date:3/19/2012

CARLSBAD, Calif., March 19, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced the launch of GeneArt® Precision TALs, generally referred to as TAL effector proteins (TALE), which will allow researchers the ability to edit genomes and control gene activity with unprecedented precision and reliability.

(Photo: http://photos.prnewswire.com/prnh/20120319/LA71858)

"We expect the GeneArt® TAL launch to be enthusiastically welcomed by the scientific community," said Nathan Wood, vice president of synthetic biology at Life Technologies. "These tools will empower our customers to carry out experiments on their 'wish lists' that they cannot readily do with existing technologies."

The development of TAL effector proteins has been closely watched by synthetic biologists, who plan to utilize them in research to develop solutions for better healthcare, agriculture and energy. Specific applications range from design of disease and drug efficacy models for the pharmaceutical industry to human gene therapy, a field that has been plagued by safety concerns due to random insertion of introduced genes and vectors into the genome.

TAL effectors can be designed to bind to specific DNA sequences selected by researchers and can deliver a variety of functional elements to activate or repress gene expression or to cut and insert DNA with precision. TAL proteins have an advantage over competing zinc finger technology in that they are simpler to design, bind with greater specificity, displaying fewer "off-target" events.

TAL effectors were originally discovered in bacteria that infect plants, where they target specific DNA sequences in the plant genome, rewiring gene expression to establish and propagate infection.  The simple TAL effector translation code allows researchers to specifically design TAL binding proteins to bind to a DNA sequence of choice. 

"Researchers give us the sequence they want to target, and we send them a gene encoding the TAL protein that will target it," said Wood. "The encoding process is that simple."

"TAL effectors have been evolved with beautiful simplicity," said Jens Boch, co-inventor of TAL technology. "We can now harness their natural properties to make a unique tool that represents a giant leap for genome editing and other applications."

GeneArt® Precision TALs are supplied as Gateway® compatible entry clones encoding a DNA binding protein for a specific customer-submitted sequence fused to a range of customer selected effector domains. Custom TALs will typically be delivered in 3 weeks after orders are placed.

The current offering includes TALs fused with gene activators, endonucleases or a vector with multiple cloning sites providing customers the ability to link their own functional domain proteins to the TAL protein, constituting a system that is easily customized to each researcher's needs. A TAL offering with a gene repression domain will be released at a future date.

The TAL Effector Technology license was jointly signed with inventors Boch, Ulla Bonas, Thomas Lahaye and Sebastian Schornack based from seminal discovery work while at Martin-Luther-Universitat Halle-Wittenberg, and with Two Blades Foundation (2Blades), which exclusively licensed plant research tool uses to Life Technologies and retains exclusive rights for commercial applications in plants.

For more information, please visit www.lifetechnologies.com/TAL

All products referenced are for Research Use Only. Not intended for diagnostic uses.

About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today's most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum with more than 50,000 products for translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent™, Applied Biosystems®,  Invitrogen™, GIBCO®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of $3.7 billion in 2011. Visit us at our website: http://www.lifetechnologies.com.

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

Life Technologies Contact
Suzanne Clancy
760-602-4545
760-717-8294 (mobile)
suzanne.clancy@lifetech.com


'/>"/>
SOURCE Life Technologies Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
3. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
4. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
5. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
6. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
7. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
8. Senesco Technologies Initiates Preclinical Studies for Cancer Target
9. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
10. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
11. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... 2017  Luminex Corporation (NASDAQ: LMNX ) (the ... the initiation of a quarterly cash dividend to its shareholders, ... will be payable on April 14, 2017 to shareholders of ... 2017. The board of directors intends for ... $0.06 to holders of its common stock, representing a planned ...
(Date:2/21/2017)... 2017 Medical Oxygen Concentrators Market: Overview ... Medical oxygen concentrators are used by ... Patients having low level of oxygen in their ... concentrators are to be used only with prescription ... oxygen concentrators work either on rechargeable lithium batteries ...
(Date:2/21/2017)... 2017 Scientists From Two Companies ... Plastic Industry  ... STEER, creator of advanced materials platform ... fields of plastics, pharmaceuticals, food and nutraceuticals, biomaterials and biorefining, ... Germany , a leading science & ...
Breaking Medicine Technology:
(Date:2/21/2017)... , ... February 21, 2017 , ... ... acquisition of the predictive analytic firm Predixion’s Healthcare IT practice. Predixion, which raised ... and is backed by giants including Accenture, GE Ventures, and Software AG ...
(Date:2/21/2017)... ... 21, 2017 , ... Along with Valentine’s Day, February marks American Heart Month, ... can lead to a lifetime of heart health. In addition, it is a ... , The Athletic Trainers’ Society of New Jersey (ATSNJ) is urging sports programs to ...
(Date:2/20/2017)... ALEXANDRIA, VA (PRWEB) , ... February 20, 2017 , ... ... with Cambridge Healthcare to open and operate a state-of-the-art memory care community in Alexandria, ... of 2018 on a site just outside of Old Town. , The three-story ...
(Date:2/20/2017)... ... February 20, 2017 , ... The StayWell Company and ... providers better manage patient health risks, foster behavior change and improve health literacy among ... world, will present a demonstration of its video capability at StayWell booth 3443 during ...
(Date:2/20/2017)... ... February 20, 2017 , ... Houston dentist , Dr. ... care at his office, Antoine Dental Center. Emergency dentistry encompasses many treatments for ... at risk for serious complications and often experience severe pain. Not only does ...
Breaking Medicine News(10 mins):